Jose Marques Lopes, PhD, science editor —

José holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimer’s disease, he moved on in 2016 to a career in science writing and communication. José is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings.

Articles by Jose Marques Lopes

Impact of Early Aggressive vs. Standard Therapy on Disability in RRMS To Be Tested in Trial

A Johns Hopkins University-initiated clinical trial is starting to enroll an estimated 900 relapsing-remitting multiple sclerosis (RRMS) patients to assess the benefits of switching therapies to prevent or reduce disability. The TREAT-MS study (NCT03500328) will evaluate whether RRMS patients with disease activity while on a traditional first-line disease-modifying therapy…

1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces

A Phase 3 trial testing an oral once-a-day therapy — ADS-5102 (amantadine) extended release capsules — in multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here